Pennsylvania is currently home to 3296 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
NCT06932809
Recruiting
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathies, such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), syndromes of genetic Frontotemporal Lobar Degeneration (genetic FTLD) as well as participants with Parkinson disease (PD),... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
05/27/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Tauopathies
Register for Updates
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289
Recruiting
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
05/27/2025
Locations: Research Site, DuBois, Pennsylvania
Conditions: Eosinophilic Asthma
Register for Updates
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
NCT06589804
Recruiting
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania
Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Hypopharyngeal Squamous Cell Carcinoma, Refractory Laryngeal Squamous Cell Carcinoma, Refractory Oral Cavity Squamous Cell Carcinoma, Refractory Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Register for Updates
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478
Recruiting
The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to last approximately 3 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Cancer Care Associates Of York, York, Pennsylvania
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
NCT06538038
Recruiting
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety and effectiveness of these standard of care regimens.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Lankenau Medical Center, Paoli, Pennsylvania
Conditions: Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
Register for Updates
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824
Recruiting
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Clinical Renal Associates, Upland, Pennsylvania
Conditions: Kidney Disease, Chronic
Register for Updates
Ketogenic Diet in Healthy Adults With Differing BMI
NCT06515912
Recruiting
The goal of this clinical trial is to examine the effect of the ketogenic diet over four weeks on blood lipid levels and risk factors for heart disease in adults with a healthy BMI compared to adults with a body mass index (BMI) in the range for obesity. The main questions it aims to answer are: * Does the ketogenic diet cause larger increases in "bad cholesterol" (low density lipoprotein-cholesterol) in adults with a healthy BMI compared to adults with BMI in the range for obesity? * Does the... Read More
Gender:
ALL
Ages:
Between 25 years and 45 years
Trial Updated:
05/27/2025
Locations: Penn State University, University Park, Pennsylvania
Conditions: Cardiovascular Diseases
Register for Updates
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
NCT06506916
Recruiting
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Ps0039 50491, Pittsburgh, Pennsylvania
Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Register for Updates
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306
Recruiting
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Local Institution - 0007, Philadelphia, Pennsylvania
Conditions: Anemia, Sickle Cell, Healthy Volunteers
Register for Updates
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288
Recruiting
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat and empagliflozin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Butler Health System Cardiovascular Consultants, Butler, Pennsylvania
Conditions: Heart Failure
Register for Updates
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
NCT06360094
Recruiting
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF. Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo look... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Clinical Research Associates of Central PA, DuBois, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Register for Updates
Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma
NCT06156410
Recruiting
The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory Ewing sarcoma and osteosarcoma.
Gender:
ALL
Ages:
Between 5 years and 40 years
Trial Updated:
05/27/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Ewing Sarcoma, Osteosarcoma
Register for Updates